Baxter International Hits New 52-Week Low at $15.87

Baxter International, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 15.87 as of March 27, 2026. This significant decline reflects a challenging year for the company, with a staggering 51.44% drop in its stock price over the past year, contrasting sharply with the S&P 500's positive performance of 11.87%. The company's financial metrics reveal underlying issues, including a price-to-earnings (P/E) ratio of 46.00, which indicates a high valuation relative to its earnings. Baxter's dividend yield stands at 1.56%, while its debt-to-equity ratio is 1.23, suggesting a considerable level of debt compared to equity. The return on equity is relatively low at 4.23%, and the price-to-book ratio is 1.92. Baxter has reported negative results for three consecutive quarters, with operating cash flow at its lowest point of USD 765 million. Additionally, net sales have decreased by 26.29%, and pre-tax profit has fallen by 45.07%. These trends highlight the company's ongoing struggles in a competitive market environment.